Skip to content

The Effect of Tranexamic Acid (TXA) on Visualization During Shoulder Arthroscopy

The Effect of Tranexamic Acid on Visualization During Shoulder Arthroscopy

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04610164
Enrollment
200
Registered
2020-10-30
Start date
2019-06-19
Completion date
2020-12-31
Last updated
2020-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Operative Bleeding, Postoperative Pain, Shoulder Arthroscopy

Brief summary

Tranexamic acid has seen an increase in use over the past decade in hip and knee arthroplasty as well as spine surgery with more recent use seen in total shoulder arthroplasty (TSA). The mechanism of action of TXA is as a lysine analogue that competitively inhibits the conversion of plasminogen to plasmin thus resulting in its antifibrinolytic activity. Investigators have showed that compared with placebo TXA had a statistically significant effect on blood and postoperative hemoglobin levels in TSA. To date there are no studies investigating the effect of TXA in arthroscopy of any kind or studies examining the ability of TXA to aid in surgeon visualization in arthroscopic procedures. The investigators of this study will use change in pump pressure as a surrogate objective measure for surgeon visualization. The hypothesis is that participants who receive TXA will have a lower change in pump pressure compared to participants who do not receive TXA.

Interventions

DRUGTranexamic acid

Prior to surgery, the patient will receive 1 gram of IV TXA

Sponsors

Rothman Institute Orthopaedics
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* participants aged 18-80 * participants with an ASA (American Society of Anesthesiologists) score 1-3 * participants with a surgical indication of full thickness small to massive rotator cuff tear.

Exclusion criteria

* pregnant females, * participants with a known allergy to tranexamic acid, * participants with active thromboembolic disease, * participants with seizure disorder, * participants with prior cerebrovascular accident (CVA), * history of cardiac stents or past history of thromboembolic disease, * presence of full-thickness subscapularis tear (\>50%), * participants with irreparable rotator cuff tears.

Design outcomes

Primary

MeasureTime frameDescription
Changes in operative factors2 hourschange in pump pressure (ΔP) during shoulder arthroscopy with a change in pump pressure of 15 mmHg set as the marker of surgeon visualization of the shoulder joint during surgery.
Postoperative pain7 daysInvestigators will be measuring whether there is a decrease in participants pain after surgery as assessed by visual analog score 7 days after surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026